News about "phase 3 trial"

Lundbeck to Present Movement Disorder Data at MDS 2026

Lundbeck presents new movement disorder research covering MSA clinical development and advanced Parkinson’s disease.

Phase 3 Trial | 05/10/2026 | By News Bureau |  116

Italfarmaco, JCR Sign License Deal for Hunter Syndrome Therapy

JCR Pharmaceuticals and Italfarmaco expand their rare disease collaboration with a global license agreement for JR-141.

Phase 3 Trial | 05/10/2026 | By News Bureau

BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma

Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.

Phase 3 Trial | 28/09/2026 | By News Bureau |  151

Japan Approves Merck's Keytruda Qlex for Subcutaneous Use

Merck’s Keytruda Qlex receives MHLW approval in Japan for subcutaneous use across all locally approved Keytruda indications.

Phase 3 Trial | 22/09/2026 | By News Bureau |  101

AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD

AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.

Phase 3 Trial | 10/09/2026 | By News Bureau |  168

Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China

Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.

Phase 3 Trial | 31/07/2026 | By News Bureau |  108

AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial

AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.

Phase 3 Trial | 10/07/2026 | By News Bureau |  228

Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan

Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.

Phase 3 Trial | 01/07/2026 | By News Bureau |  341

US Approves TRUQAP for PTEN-Deficient Metastatic Prostate Cancer

TRUQAP (capivasertib) has been approved in the US as the first targeted treatment for PTEN-deficient metastatic Hormone-Sensitive Prostate Cancer (mHSPC). The approval is supported by phase 3 CAPItello-281 data showing a 19 percent reduction in the risk of disease progression or death.

Phase 3 Trial | 15/06/2026 | By News Bureau |  145